For example, the Food and Drug Administration (FDA) approved patozumab and TDM-1 in HER2-positive advanced breast cancer patients in 2012 and 2013, respectively (30, 31), Pfizer’s Palbiclib as an initial endocrine therapy scheme in 2015, and the PARP inhibitor Olaparib for treating BRCA1 or BRCA2 gene mutation breast cancer patients (32). This evidence concerns the gene BRCA1 and breast cancer.